Blueprint Medicines Announces Incentive Grants Under NASDAQ Enrollment Rule 5635 (c) (4)
Posted: October 5, 2021 at 4:01 p.m. EDT|Update: 4 hours ago
CAMBRIDGE, Mass., October 5, 2021 / PRNewswire / – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective in October 1, 2021, the Compensation Committee of the Board of Directors of Blueprint Medicines granted unqualified stock options to purchase a total of 24,068 common shares and a total of 12,033 restricted stock units (RSUs) at eight new employees as part of Blueprint Medicines’ 2020 incentive plan. .
The 2020 Incentive Plan is used exclusively for granting stock awards to people who were not previously an employee or non-employee director of Blueprint Medicines, as hiring incentive material of that person at Blueprint Medicines, in accordance with Rule 5635 (c) (4) of the NASDAQ Listing Rules.
The options have an exercise price of $ 101.72 per share, which is equal to the closing price of the common shares of Blueprint Medicines on October 1, 2021. Each option will vest for 25% of the shares underlying that option on the first anniversary of the grant date and for an additional 1/48 of the shares underlying the option monthly thereafter, in each case, subject to the continued employment of each of these employees. on each acquisition date. Each RSU will vest 25% of the shares underlying the RSU grant on the first anniversary of the grant date and an additional 25% of the shares underlying the RSU grant each year by thereafter, subject to the maintenance of the employment of each of these employees at each acquisition Date. Options and RSUs are subject to the terms and conditions of the Blueprint Medicines 2020 Incentive Plan, and the terms and conditions of the Stock Option and RSU Agreement covering the grant.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. By applying an approach that is both precise and agile, we create drugs that selectively target genetic factors, with the aim of staying one step ahead through the stages of the disease. Since 2011, we have leveraged our research platform, including our expertise in molecular targeting and our world-class drug design capabilities, to rapidly and reproducibly translate science into a broad portfolio of therapeutic therapies. precision. Today, we deliver approved drugs directly to patients in United States and Europe, and we are advancing several programs globally for genomically defined cancers, systemic mastocytosis and cancer immunotherapy. For more information visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:
SOURCE Blueprint Medicines Corporation
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.